JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...

Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...

Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is ...

ImmunityBio (NasdaqGS:IBRX) has had its resubmitted supplemental Biologics License Application for ANKTIVA plus BCG in papillary non muscle invasive bladder cancer formally acknowledged by the FDA.

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...

A team led by researchers at Baylor College of Medicine has identified flavonoids, natural compounds found in plants, that are toxic to bladder cancer cells cultured in the lab. The researchers report ...

For five decades, scientists have known about a notorious cancer-causing enzyme called SRC. But they always assumed it only ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...